Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment...

{
  "signal_id": "3e4c4f17-9c91-4110-7784-ad87002bda74",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-29T07:00:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lillys-foundayo-orforglipron-17-2-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison-302891494.html",
    "title": "Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison",
    "excerpt": "Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg INDIANAPOLIS , Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings are based on an indirect treatment comparison of Foundayo 17.2 mg against oral semaglutide 25 mg, drawing on data from ACHIEVE-3 and PIONEER PLUS. 1,2,3,4 Presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, these results add to a growing body of evidence supporting Foundayo's efficacy. \"For someone managing type 2 diabetes, the choice between treatments is a decision that impacts their life every day,\" said Deborah Horn, D.O., director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. \"Having data to help us compare available medications provides clinicians the opportunity to make informed treatment choices that...",
    "product": "Orforglipron",
    "summary": "Eli Lilly and Company is studying its drug Orforglipron as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA2972127&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Orforglipron",
      "full_text": "Orforglipron",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-29T07:00:00Z",
    "article_sentence": "Orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence."
  }
}

curl https://signals.autobound.ai/v1/signals/3e4c4f17-9c91-4110-7784-ad87002bda74 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'